EGFR/BRAFV600E-IN-4 

EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual EGFR and BRAF^V600E inhibitor with IC₅₀ values of 61 nM and 43 nM, respectively. EGFR/BRAFV600E-IN-4 arrests cell cycle, induces apoptosis in both early and late stages and inhibits cancer cells growth in vitro, and has a broad anticancer activity^[1].

EGFR/BRAFV600E-IN-4 (0.01-100 μM) has broad-spectrum anti-proliferative activity with GI₅₀ values ranging from 1.66 to >100 μM. EGFR/BRAFV600E-IN-4 (1.56-100 nM, 48 h) inhibits cells growth of A-549, Panc-1, HT-29, MCF-7 with IC₅₀ values ranging from 24 nM to 27 nM, but exhibits a safety profile versus MCF-10 A cells with cell viability of 91%. EGFR/BRAFV600E-IN-4 (24 nM, 24 h) arrests cells at the G0/G1 phase and block the transition from the G1 phase to the S and G2/M phases, induces apoptosis in both early and late stages.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

384.45

C₂₂H₁₆N₄OS

C1(SCC2=CC=CC=C2)=NN=C(C3=CC=C4NC(C5=CC=CC=C5)=NC4=C3)O1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fatma Fouad Hagar, et al. New antiproliferative 1,3,4-oxadiazole/benzimidazole derivatives: Design, synthesis, and biological evaluation as dual EGFR and BRAFV600E inhibitors. Bioorganic Chemistry. Volume 157, April 2025, 108297.